Cardiol Therapeutics (CRDL) Depreciation & Amortization (CF) (2020 - 2026)

Cardiol Therapeutics (CRDL) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $19476.4 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 11.85% year-over-year to $19476.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75051.7 (down 29.27% YoY) and the FY2025 annual result came in at $73130.6, down 37.23% from the prior year.
• Depreciation & Amortization (CF) improved to $19476.4 in Q1 2026, from $18627.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $34713.7 in Q4 2024 to a low of $17413.2 in Q1 2025.
• A 5-year average of $25691.7 and a median of $25665.1 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) rose 27.66% — and 2025, when it tumbled 46.34%.
• Tracing CRDL's Depreciation & Amortization (CF) over 5 years: stood at $27201.3 in 2022, then gained by 23.27% to $33531.5 in 2023, then rose by 3.53% to $34713.7 in 2024, then plunged by 46.34% to $18627.0 in 2025, then rose by 4.56% to $19476.4 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $19476.4 (Q1 2026), $18627.0 (Q4 2025), and $18566.3 (Q3 2025), per Business Quant data.